Compare Stocks: CYTK, ALNY, ROIV, and UTHR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$158.00 -4.2%	$234.93	$156.00 ▼ $479.79	$31.10B	0.28	1.41 million shs	4.76 million shs
CYTK Cytokinetics	$62.03 -1.5%	$67.21	$58.05 ▼ $88.31	$7.84B	0.41	1.77 million shs	1.56 million shs
ROIV Roivant Sciences	$35.89 -2.8%	$36.64	$19.30 ▼ $42.50	$26.66B	1.1	6.64 million shs	5.70 million shs
UTHR United Therapeutics	$596.13 -0.4%	$528.76	$430.02 ▼ $609.99	$25.15B	0.49	786,841 shs	402,365 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	-4.24%	-30.60%	-28.09%	-27.85%	-65.35%
CYTK Cytokinetics	-1.52%	+2.14%	-5.44%	-21.09%	-2.45%
ROIV Roivant Sciences	-2.76%	-0.44%	+0.48%	+3.76%	+79.54%
UTHR United Therapeutics	-0.43%	+0.55%	+10.05%	+14.93%	+33.83%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$158.00 -4.2%	$234.93	$156.00 ▼ $479.79	$31.10B	0.28	1.41 million shs	4.76 million shs
CYTK Cytokinetics	$62.03 -1.5%	$67.21	$58.05 ▼ $88.31	$7.84B	0.41	1.77 million shs	1.56 million shs
ROIV Roivant Sciences	$35.89 -2.8%	$36.64	$19.30 ▼ $42.50	$26.66B	1.1	6.64 million shs	5.70 million shs
UTHR United Therapeutics	$596.13 -0.4%	$528.76	$430.02 ▼ $609.99	$25.15B	0.49	786,841 shs	402,365 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	-4.24%	-30.60%	-28.09%	-27.85%	-65.35%
CYTK Cytokinetics	-1.52%	+2.14%	-5.44%	-21.09%	-2.45%
ROIV Roivant Sciences	-2.76%	-0.44%	+0.48%	+3.76%	+79.54%
UTHR United Therapeutics	-0.43%	+0.55%	+10.05%	+14.93%	+33.83%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.65	Moderate Buy	$305.86	93.58% Upside
CYTK Cytokinetics	2.86	Moderate Buy	$105.44	69.99% Upside
ROIV Roivant Sciences	2.79	Moderate Buy	$46.55	29.69% Upside
UTHR United Therapeutics	2.73	Moderate Buy	$667.07	11.90% Upside

Current Analyst Ratings Breakdown

Latest CYTK, ALNY, ROIV, and UTHR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/2/2026	ALNY Alnylam Pharmaceuticals	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$450.00 ➝ $380.00
11/2/2026	ALNY Alnylam Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$429.00 ➝ $323.00
11/2/2026	ALNY Alnylam Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Hold	$315.00 ➝ $225.00
10/30/2026	ALNY Alnylam Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$550.00 ➝ $329.00
10/30/2026	ALNY Alnylam Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$290.00
10/30/2026	ALNY Alnylam Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$460.00 ➝ $287.00
10/30/2026	ALNY Alnylam Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Outperform	$420.00 ➝ $315.00
10/30/2026	ALNY Alnylam Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$425.00 ➝ $375.00
10/30/2026	ALNY Alnylam Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$350.00 ➝ $320.00
10/30/2026	ALNY Alnylam Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$482.00 ➝ $354.00
10/28/2026	ROIV Roivant Sciences	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$46.00 ➝ $56.00

(Data available from 11/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$3.71B	5.69	$1.90 per share	83.11	$5.97 per share	26.47
CYTK Cytokinetics	$67.67M	114.06	N/A	N/A	($5.39) per share	-11.51
ROIV Roivant Sciences	$8.26M	3,138.51	N/A	N/A	$7.35 per share	4.88
UTHR United Therapeutics	$3.18B	8.03	$33.53 per share	17.78	$164.81 per share	3.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$19.26	8.20	17.50	N/A	15.26%	84.93%	14.30%	N/A
CYTK Cytokinetics	-$784.96M	-$7.22	N/A	N/A	N/A	-1,321.12%	N/A	-51.01%	11/4/2026 (Estimated)
ROIV Roivant Sciences	-$299.77M	-$0.53	N/A	N/A	N/A	-3,534.96%	-22.94%	-21.53%	11/9/2026 (Estimated)
UTHR United Therapeutics	$1.33B	$27.95	21.33	19.35	4.25	41.56%	20.18%	17.98%	11/4/2026 (Estimated)

Latest CYTK, ALNY, ROIV, and UTHR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q2 2027	ROIV Roivant Sciences	-$0.3666	N/A	N/A	N/A	$4.15 million	N/A
11/4/2026	Q3 2026	CYTK Cytokinetics	-$1.44	N/A	N/A	N/A	$41.88 million	N/A
11/4/2026	Q3 2026	UTHR United Therapeutics	$6.01	N/A	N/A	N/A	$781.14 million	N/A
10/29/2026	Q3 2026	ALNY Alnylam Pharmaceuticals	$1.66	$16.26	+$14.60	$15.72	$1.43 billion	$1.46 billion
8/7/2026	Q1 2027	ROIV Roivant Sciences	-$0.2996	-$0.26	+$0.0396	-$0.26	$2.06 million	$1.44 million
8/6/2026	Q2 2026	CYTK Cytokinetics	-$1.63	-$1.50	+$0.13	-$1.50	$17.59 million	$28.62 million
8/5/2026	Q2 2026	UTHR United Therapeutics	$6.86	$7.27	+$0.41	$7.27	$804.65 million	$783.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.75	3.05	2.99
CYTK Cytokinetics	N/A	6.66	6.66
ROIV Roivant Sciences	N/A	16.72	16.72
UTHR United Therapeutics	N/A	5.73	5.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
CYTK Cytokinetics	N/A
ROIV Roivant Sciences	64.76%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
CYTK Cytokinetics	2.60%
ROIV Roivant Sciences	8.80%
UTHR United Therapeutics	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.81 million	132.79 million	Optionable
CYTK Cytokinetics	673	124.43 million	121.20 million	Optionable
ROIV Roivant Sciences	721	722.32 million	658.76 million	Optionable
UTHR United Therapeutics	1,400	42.89 million	39.20 million	Optionable

CYTK, ALNY, ROIV, and UTHR Headlines

Recent News About These Companies

United Therapeutics (UTHR) Expected to Release Quarterly Earnings on Wednesday

2 hours ago | americanbankingnews.com

United Therapeutics (NASDAQ:UTHR) CEO Sells $5,700,855.00 in Stock

3 hours ago | insidertrades.com

United Therapeutics (NASDAQ: UTHR) CEO Rothblatt sells $5.65 million of option shares

4 hours ago | americanbankingnews.com

United Therapeutics (UTHR) to report earnings tomorrow: here is what to expect

4 hours ago | financialcontent.comF

United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

November 2 at 5:07 PM | marketbeat.com

United Therapeutics Corporation $UTHR Stock Purchased by Profund Advisors LLC

November 2 at 7:40 AM | marketbeat.com

SGIOY vs. UTHR: Which Stock Is the Better Value Option?

October 30, 2026 | zacks.com

United Therapeutics (NASDAQ:UTHR) Sets New 52-Week High - Here's What Happened

October 30, 2026 | marketbeat.com

United Therapeutics (NASDAQ:UTHR) Stock Price Target Cut by JPMorgan Chase & Co.

October 30, 2026 | americanbankingnews.com

United Therapeutics (UTHR) Cleared To Start Trial For New Pulmonary Hypertension Therapy

October 29, 2026 | finance.yahoo.com

United Therapeutics (NASDAQ:UTHR) Stock: Insider Martine Rothblatt Sells 9,500 Shares

October 29, 2026 | marketbeat.com

29,327 United Therapeutics Corporation $UTHR Shares Sold by Simplify Asset Management Inc.

October 29, 2026 | marketbeat.com

United Therapeutics receives FDA clearance to begin clinical trial of inhaled PAH treatment

October 28, 2026 | msn.com

United Therapeutics Rising Ahead of Next Earnings Report

October 28, 2026 | finance.yahoo.com

United Therapeutics (NASDAQ:UTHR) Stock Price Target Lowered at JPMorgan Chase & Co.

October 28, 2026 | marketbeat.com

Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for

October 28, 2026 | zacks.com

United Therapeutics Announces FDA Clearance to Proceed with Clinical Trial for Treprostinil-Iloprost SMI in Pulmonary Arterial Hypertension

October 28, 2026 | marketscreener.comM

United Therapeutics Gets FDA Clearance To Begin Trial Of Inhaled PAH Therapy

October 28, 2026 | rttnews.com

United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Company Stock

October 27, 2026 | insidertrades.com

United Therapeutics (NASDAQ: UTHR) CEO sells shares in prearranged plan

October 27, 2026 | americanbankingnews.com

United Therapeutics Corporation $UTHR Shares Sold by Tower View Wealth Management LLC

October 26, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYTK, ALNY, ROIV, and UTHR Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$158.00 -7.00 (-4.24%)

Closing price 11/2/2026 04:00 PM Eastern

Extended Trading

$161.49 +3.49 (+2.21%)

As of 07:19 AM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Cytokinetics NASDAQ:CYTK

$62.03 -0.96 (-1.52%)

Closing price 11/2/2026 04:00 PM Eastern

Extended Trading

$62.35 +0.32 (+0.51%)

As of 07:13 AM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Roivant Sciences NASDAQ:ROIV

$35.89 -1.02 (-2.76%)

Closing price 11/2/2026 04:00 PM Eastern

Extended Trading

$35.89 0.00 (0.00%)

As of 06:27 AM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

United Therapeutics NASDAQ:UTHR

$596.13 -2.59 (-0.43%)

Closing price 11/2/2026 04:00 PM Eastern

Extended Trading

$596.45 +0.32 (+0.05%)

As of 11/2/2026 07:30 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CYTK, ALNY, ROIV, and UTHR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CYTK, ALNY, ROIV, and UTHR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CYTK, ALNY, ROIV, and UTHR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYTK, ALNY, ROIV, and UTHR Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Cytokinetics NASDAQ:CYTK

Roivant Sciences NASDAQ:ROIV

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CYTK, ALNY, ROIV, and UTHR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CYTK, ALNY, ROIV, and UTHR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CYTK, ALNY, ROIV, and UTHR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYTK, ALNY, ROIV, and UTHR Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Cytokinetics NASDAQ:CYTK

Roivant Sciences NASDAQ:ROIV

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools